MNKD Mannkind Dashboard

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

Company profile

Ticker

MNKD

Exchange

NASDAQ

Website

www.mannkindcorp.com/

CEO

Michael Castagna

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

SEC CIK

0000899460

Corporate docs

Articles of Incorporation & Bylaws

IRS number

133607736

MNKD stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

60 Biggest Movers From Yesterday

26 Mar 21

Gainers Olink Holding AB (NASDAQ: OLK) shares surged 80% to close at $36.00 on Thursday after the company priced its IPO at $20 per share.

12 Health Care Stocks Moving In Thursday's After-Market Session

18 Mar 21

Gainers SenesTech (NASDAQ:SNES) stock moved upwards by 20.83% to $2.03 during Thursday's after-market session. SenesTech's trading volume hit 1.3 million shares by close, accounting for 146.36% of its average volume over the last 100 days. The market value of their outstanding shares is at $16.3 million.

SVB Leerink Maintains Outperform on MannKind, Raises Price Target to $5

5 Mar 21

SVB Leerink analyst Thomas Smith maintains MannKind (NASDAQ:MNKD) with a Outperform and raises the price target from $3 to $5.

9 Health Care Stocks With Unusual Options Alerts In Today's Session

2 Mar 21

82 Biggest Movers From Yesterday

2 Mar 21

Press releases

Pro users get this 30m faster

MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference

10 Mar 21

WESTLAKE VILLAGE, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine

MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference

2 Mar 21

WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine

MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering

2 Mar 21

WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the

Vertice launches THYQUIDITY™ (levothyroxine sodium) Oral Solution

24 Feb 21

MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference

18 Feb 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

25 Feb 21

13 Apr 21

31 Dec 21

Financial summary

Financial statements Chart MNKD financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Mannkind earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	67.16M	67.16M	67.16M	67.16M	67.16M	67.16M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	8.8M	4.79M	(positive/no burn)	2.34M
Cash used (since last report)	n/a	n/a	30.42M	16.54M	n/a	8.1M
Cash remaining	n/a	n/a	36.75M	50.62M	n/a	59.06M
Runway (months of cash)	n/a	n/a	4.2	10.6	n/a	25.2

Beta Read what these cash burn values mean

Recent insider trades

MNKD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Mar 21	Michael Castagna	Common Stock,$.01 par value	Buy	Aquire P	Yes	No	3.38	3,000	10.14K	3,000
31 Jan 21	Stuart A Tross	Common Stock, $0.01 Par Value	Buy	Aquire P	No	No	1.33	5,000	6.65K	481,991
31 Jan 21	Michael Castagna	Common Stock, $0.01 Par Value	Buy	Aquire P	No	No	1.33	5,000	6.65K	1,117,560
31 Jan 21	Steven B. Binder	Common Stock, $0.01 Par Value	Buy	Aquire P	No	No	1.33	1,557	2.07K	398,822
28 Dec 20	Stuart A Tross	Common Stock, $.01 Par Value	Payment of exercise	Dispose F	No	No	3.33	1,729	5.76K	476,991

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

MNKD institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

30.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	146	136	+7.4%
Opened positions	29	16	+81.3%
Closed positions	19	21	-9.5%
Increased positions	52	35	+48.6%
Reduced positions	36	36	–

13F shares	Current	Prev Q	Change
Total value	446.41M	227.75M	+96.0%
Total shares	75.1M	68.86M	+9.1%
Total puts	1.37M	795.8K	+71.7%
Total calls	969.8K	628.9K	+54.2%
Total put/call ratio	1.4	1.3	+11.3%

Largest owners	Shares	Value	Change
BLK Blackrock	17.98M	$56.26M	+1.8%
Vanguard	12.29M	$38.47M	+8.5%
STT State Street	8.85M	$27.69M	+137.4%
FMR	3.73M	$11.68M	-18.1%
Avoro Capital Advisors	3.5M	$10.96M	NEW
Geode Capital Management	3.29M	$10.29M	+7.7%
NTRS Northern Trust	2.53M	$7.91M	-0.7%
Millennium Management	2.07M	$6.48M	NEW
Charles Schwab Investment Management	1.5M	$4.69M	+2.0%
Two Sigma Advisers	1.46M	$4.56M	+72.3%

Largest transactions	Shares	Bought/sold	Change
STT State Street	8.85M	+5.12M	+137.4%
Avoro Capital Advisors	3.5M	+3.5M	NEW
Emerald Advisers	0	-3.16M	EXIT
Emerald Mutual Fund Advisers Trust	0	-2.92M	EXIT
Millennium Management	2.07M	+2.07M	NEW
MS Morgan Stanley	1.19M	-2.03M	-63.0%
Vanguard	12.29M	+961.64K	+8.5%
FMR	3.73M	-822.78K	-18.1%
EAM Global Investors	702.98K	+702.98K	NEW
Two Sigma Advisers	1.46M	+611.3K	+72.3%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Acorda Therapeutics • United Therapeutics • Ngm Biopharmaceuticals

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Absent, accuracy, AfrezzaAssist, Alejandro, anesthesiologist, appliance, batch, belief, beneficiary, Biden, Britain, buyer, call, calling, cannabidiol, cap, CECL, Chancery, Chase, choice, chosen, churn, clarity, clofazimine, communicable, complaint, congenital, constitutionality, contemplated, contrary, controversy, County, covertly, culture, denial, di, dictated, disbursement, discourage, discretionary, diverge, doctrine, DPI, duration, duty, economy, Electric, electrical, eleven, EMA, endocrine, energy, entertain, epidemic, evidenced, expedited, facially, faith, fiduciary, forfeited, forgiven, forum, fullest, Galindo, GE, Great, home, hospital, hypothalamic, hypothyroidism, imatinib, impede, inapplicable, inconsistent, Indiana, indispensable, Inline, instance, interpolated, interstitial, intervention, joinder, JPMorgan, Kingdom, lab, leverage, levothyroxine, LOI, Los, Lyumjev, magnitude, margin, mathematical, Medtronic, Mexico, MHRA, midst, Monterrey, movement, mycobacterial, NaN, nationwide, nebulized, nonemployee, Northern, NTM, nurse, oppose, orphan, overtly, pandemic, Paycheck, percentile, pituitary, PNQ, PPP, preliminary, prioritization, prioritize, prorated, pulmonology, QrumPharma, quarantined, qui, reacquired, reassessment, recession, recurrent, reexamining, refund, regime, regrettable, reopened, residence, resignation, resumed, reward, risky, RSU, SBA, secondary, sentiment, sequester, shelter, situation, sodium, solid, speculative, spread, stretch, strike, tam, tangible, tariff, telecommunication, terrorism, tertiary, threat, Thyquidity, thyroidal, tie, timeframe, TSR, Tyvaso, unbilled, underwent, unemployment, unforgiven, unimproved, unnecessary, unrecoverable, usability, vaccination, venue, Vertice, vi, vii, virtual, visit, war, week, whistleblower, wholly, withheld, workweek, worth, XBRL

Removed: absorption, advisory, advocacy, Alinaya, allegation, Amylin, approving, attest, augment, beneficially, biology, body, borrow, broader, capability, Center, chemistry, claiming, Clinic, Concurrently, confirm, consistently, consultant, contracting, convene, Dame, deposited, detailing, dispersed, embedded, excretion, explanatory, expressed, feature, finalize, Fujisawa, geographically, glucose, Graduate, graduating, guided, healthy, injected, inspect, institution, institutional, integrated, internally, introduced, invested, investigator, IRB, Kellogg, Kendall, malfunctioned, McCauley, mealtime, metabolism, Minnesota, municipal, NED, Nicollet, Northridge, Northwestern, Notre, Olaf, optimal, outweigh, overlap, paragraph, Park, participating, Patrick, payor, pertain, pharmacology, placement, population, potency, producing, protocol, purity, rank, rated, recalling, recur, refusing, release, repeated, Rosabel, round, seizing, separated, sequential, shown, South, St, supplement, suspending, tolerability, tolerance, traditionally, unacceptable, unaudited, underperform, undertaken, unqualified, unwarranted, withdrawing, Yamanouchi

From filing 10-K 2020 FY